Orion Group Financial Statement documents 2018 and Corporate Governance Statement published
ORION CORPORATION STOCK EXCHANGE RELEASE 4 MARCH 2019 at 12.00 EET
Orion Group's Financial Statement documents for 2018 have been published. The documents are available in Finnish and English on the Company's website at http://www.orion.fi/en.
The official Financial Statement documents, which include the Financial Statements, the Report by the Board of Directors and the Auditor's Report are available in Finnish at http://www.orion.fi/yhtiokokous2019.
Orion's Corporate Governance Statement for year 2018, adopted by the Board of Directors, is published as a separate report in Finnish and English on the Company's website at http://www.orion.fi/en.
| Olli Huotari |
SVP, Corporate Functions
| Terhi Ormio |
Lilli Riikonen, Communications Manager, tel. +358 50 966 2319
Orionintie 1A, FI-02200 Espoo
Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2018 amounted to EUR 977 million and the company had about 3,200 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.